The report entitled “Pharmacological Research in the Era of Personalized Precision Medicine”, prepared by the Roche Institute, has had the participation of Valentín Ceña, responsible for the implementation of the Complementary Biotechnology Plan in Castilla-La Mancha and who leads the Laboratory of the Neurodeath Unit of the Faculty of Medicine of the University of Castilla-La Mancha. to which our research group belongs.
The Anticipating Reports, developed within the framework of the Observatory of Trends in Future Medicine promoted by the Roche Institute Foundation, arise with the aim of contributing to the generation and sharing of advances in emerging areas of knowledge related to personalized precision medicine and that will be key in the medicine of the future.
This recently published report, in which Valentín Ceña has participated, is coordinated by Mabel Loza, professor of Pharmacology at the University of Santiago de Compostela and coordinator of the BioFarma Research group. In addition, experts such as Joan Albanell, Head of the Medical Oncology Service at Hospital del Mar and Head of the Oncology Service at HM Delfos Hospital in Barcelona and María Jesús Blanco, Vice President of Chemical Sciences of the Division of Medicinal Chemistry at Atavistik Bio, Cambridge (Massachusetts), have also participated in its preparation.
“The report addresses a series of challenges faced by pharmacological research to integrate tools and technological advances that already exist and/or are being developed, such as genomic sequencing, digitalization and artificial intelligence to advance in the framework of personalized precision medicine,” explains Valentín Ceña.
Personalized precision medicine seeks to offer the most appropriate, effective and safe treatment for each patient, considering their individual characteristics. To achieve this, it is necessary to change the approach, not only of the approach in clinical practice of diseases, but throughout the entire pharmacological research process, from the early stages of research and development of new innovative treatments.
According to this report, pharmacological research is undergoing a profound transformation thanks to the use of all the tools and technological advances available within the framework of personalized precision medicine, such as genomic sequencing, as well as the use of knowledge derived from the analysis of big data and artificial intelligence tools.
In this way, it is possible to identify not only genetic predispositions to diseases, but also individual responses to pharmacological treatments based on the genomic profile and biomarkers that will facilitate the personalization of drugs, minimizing side effects and optimizing their effectiveness.
Current trends in basic and preclinical research are aimed at the development of new strategies for the identification of therapeutic targets, mechanisms of action and new molecules and drugs, with the aim of moving towards a more equitable, inclusive and people-centred medicine.
